Obstetrics & Gynecology Science10.5468/ogs.2015.58.2.1752015582175Endometrial cancer occurence five years after breast cancer in BRCA2 mutation patientSang Eun Oh, Soo Hyun Kim, Mee Seon Kim, Min Kyu Kim,,
Obstetrics & Gynecology Science10.5468/ogs.2015.58.4.3312015584331Comment on: Endometrial cancer occurrence five years after breast cancer in BRCA2 mutation patientMin Chul Choi, Mi Sun Kim, Gee Hoon Lee, Jun Mo Lee,,
npj Breast Cancer10.1038/s41523-019-0139-1201951Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal CarcinomatosisPedro Exman, Robert M. Mallery, Nancy U. Lin, Heather A. Parsons,,
Breast Cancer Research10.1186/bcr38720013S1Constitutional genomic instability of 9p23-24 in BRCA2 mutation carriersL Savelyeva, M Schwab,,
Breast Cancer Online10.1017/s1470903105002890200589Update on chemoprevention in BRCA1 and BRCA2 mutation carriersM. Stumacher, S. M. Domchek
Breast Cancer Research10.1186/bcr953200471Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer familiesHannaleena Eerola, Päivi Heikkilä, Anitta Tamminen, Kristiina Aittomäki, Carl Blomqvist, Heli Nevanlinna,,
Clinical Breast Cancer10.1016/s1526-8209(11)70943-0200345311-312A Benefit of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast CancerHeather DeGrendele, Joyce A. O'Shaughnessy,
Cancers10.3390/cancers1012047720181012477Screening BRCA1 and BRCA2 Mutation Carriers for Breast CancerEllen Warner
Breast Cancer Research10.1186/bcr9520002S1A novel BRCA2 gene mutation, 4081 insA, in a Finnish breast/ovarian cancer family associated with favourable clinical courseJ Hartikainen, V Kataja, A Mannermaa,,
Breast Cancer Research10.1186/bcr70200024Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriersRosalind A Eeles,,